Arctic Vision collects $100M to bring US eye disease candidates overseas

Nicole DeFeudis

Editor

With three eye disease candidates, in-licensed from the US, Shanghai-based Arctic Vision has hooked more than $100 million to see the therapies to the Chinese …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arctic Vision collects $100M to bring US eye disease candidates overseas

Nicole DeFeudis

Editor

Sign up to read this article for free.

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Bristol Myers sues the federal government over 340B, following other drugmakers

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Arc­tic Vi­sion col­lects $100M to bring US eye dis­ease can­di­dates over­seas

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Arctic Vision collects $100M to bring US eye disease candidates overseas

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Bristol Myers sues the federal government over 340B, following other drugmakers

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks